Steatohepatitis/Metabolic Liver Disease News

Dietary supplementation with resistant starch reduced intrahepatic triglyceride content and may help manage disease by altering gut microbiota among patients with nonalcoholic fatty liver disease, according to data in Cell Metabolism.

Liver disease was the primary cause of death in patients with alcohol-related liver disease several years after diagnosis, with the risk for mortality almost three times higher in those with decompensated cirrhosis, according to research.

A surge of blockbuster anti-obesity drugs has dramatically changed the landscape for chronic weight management and opened new avenues of research in gastrointestinal and liver disease alongside concerns for potential GI side effects.

Although fibrosis-4 index and NAFLD fibrosis score did not significantly differ in diagnosing advanced fibrosis in nonalcoholic fatty liver disease, fibrosis-4 may be a better screening tool in lean patients, according to a study.

After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.

Novo Nordisk has awarded a $9.57 million grant supporting a clinical trial at the University of California San Diego NAFLD Research Center to evaluate the use of semaglutide in patients with fibrosis due to nonalcoholic fatty liver disease.

Topline findings from the phase 2a DUET trial showed that Tern Pharmaceuticals’ oral thyroid hormone receptor-beta agonist achieved significant reductions in liver fat content among patients with nonalcoholic steatohepatitis.

The AGA applauded the reintroduction of the Treat and Reduce Obesity Act into the 118th Congress as this bill would expand Medicare coverage for screening and treatment of obesity by health care providers specializing in obesity care.

A familial risk score comprised of age, obesity, type 2 diabetes and family history of nonalcoholic fatty liver disease accurately identified advanced fibrosis among first-degree relatives, according to researchers.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.